cs.LGNov 2, 2026

Probabilistic Steering of Generative Priors for Lab-in-the-Loop Antibody Optimization

Authors: Anisha Parsan, Sebastian Ober, Calvin McCarter, Nick Bhattacharya, Hunter Elliott

Organizations: BigHat Biosciences

Abstract

Therapeutic antibody development is often framed as comprising two discrete stages: initial discovery of novel binders followed by iterative optimization to refine these hits into therapeutic-grade molecules. Models and methods often reflect these stages, with generative structure models applied to discovery and probabilistic black-box optimization methods applied to refinement. Here we propose to unify these stages by smoothly transitioning a generative discovery model into iterative optimization, allowing the handoff between the structure-based prior and supervision from wet lab data to be guided by the posterior uncertainty of a probabilistic surrogate. We show that this yields improvements in optimization efficiency in the low-N regime, as well as improved diversity amongst the optimized molecules.

Figures & tables

Appendix figures & tables12 assets

Supplementary material from the paper’s appendix.

Appendix

Explore similar work

Apr 15, 2026

BOAT: Navigating the Sea of In Silico Predictors for Antibody Design via Multi-Objective Bayesian Optimization

Antibody lead optimization is inherently a multi-objective challenge in drug discovery. Achieving a balance between different drug-like properties is crucial for the development of viable candidates, and this search becomes exponentially challenging as desired properties grow. The ever-growing zoo of sophisticated in silico tools for predicting antibody properties calls for an efficient joint optimization procedure to overcome resource-intensive sequential filtering pipelines. We present BOAT, a versatile Bayesian optimization framework for multi-property antibody engineering. Our `plug-and-play' framework couples uncertainty-aware surrogate modeling with a genetic algorithm to jointly optimize various predicted antibody traits while enabling efficient exploration of sequence space. Through systematic benchmarking against genetic algorithms and newer generative learning approaches, we demonstrate competitive performance with state-of-the-art methods for multi-objective protein optimization. We identify clear regimes where surrogate-driven optimization outperforms expensive generative approaches and establish practical limits imposed by sequence dimensionality and oracle costs.
Jul 21, 2026

ABOPD: Antibody CDR Design via On-Policy Distillation

Antibodies are essential therapeutic molecules, and their complementarity-determining regions (CDRs) form the primary antigen-recognition interface. Recent protein generative models have demonstrated broad capabilities in biomolecular design, yet post-training strategies for downstream objectives remain limited. Standard denoising training operates on noisy states obtained by perturbing native structures, whereas recursive generation proceeds through model-generated intermediate states. For flexible antibody CDR loops such as CDR-H3, this mismatch can allow backbone deviations to accumulate along the denoising trajectory and compromise antigen-facing loop geometry. We introduce ABOPD, an antibody design framework based on on-policy distillation that leverages privileged native geometry during training to supervise states visited along the model's own denoising trajectories. With this fine-grained structural supervision, ABOPD substantially improves structural recovery on RAbD CDR-H3 generation, reducing RMSD by 0.42 Å (from 2.37 Å to 1.95 Å) and outperforming supervised fine-tuning and offline distillation controls, offering a path to higher-fidelity protein design.
Jul 14, 2026

Sample Efficient Generative Optimization for Molecular Design

Molecular optimization in drug discovery, materials design, and catalysis requires searching vast chemical spaces under tight evaluation budgets, since high-fidelity oracles and experimental measurements are costly. The practical impact of an optimization method therefore hinges on its sample efficiency: how few evaluations it needs to find strong candidates. We introduce Sample Efficient Generative Optimization (SEGO), a framework for Bayesian optimization on adaptively generated molecules. In SEGO, a probabilistic surrogate model forms a hypothesis about where hits lie in chemical space, a generative model is steered to propose candidates in that region, the most promising candidate is selected via an acquisition function, and the resulting oracle call is used both to sharpen the surrogate and to anchor the generator in real reward. SEGO attains state-of-the-art performance on the practical molecular optimization (PMO) benchmark using only one tenth of the oracle calls consumed by other methods, and on a multiparameter docking task it reaches ten hits in roughly half the oracle calls of existing approaches. These gains move molecular optimization closer to campaigns driven by direct experimental feedback.